Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

ARMO BioSciences is a US private company that develops immunotherapies for the treatment of cancer, cardiovascular diseases, fibrosis and inflammation. It raised $67 million in a venture capital investment, as reported in the PharmSource Lead Sheet on August 31, 2017.

Corporate Highlights

  • ARMO BioSciences was founded in 2012
  • Corporate Headquarters: Redwood City, CA

Sourcing Opportunities

  • ARMO BioSciences plans to use the proceeds to fund ongoing clinical trials for its pipeline, including:
    • AM0010 – To a initiate a Phase II/III study:
      • For treatment of NSCLC & renal cell cancer
      • Dosage Form: Parenteral
      • Nature of API: PEGylated product; Biologic – Protein – Recombinant
      • Therapeutic Areas: Oncology – Immunotherapy
    • AM0001 – To complete preclinical development:
      • For treatment of cancer
      • Dosage Form: Parenteral
      • Nature of API: Biologic – Monoclonal antibody
      • Therapeutic Areas: Oncology – Immunotherapy
    • AM0012 – To complete preclinical development:
      • For treatment of cancer
      • Dosage Form: Unknown
      • Nature of API: Biologic – Protein – Recombinant
      • Therapeutic Areas: Oncology – Immunotherapy

    Previous Financings

    • February 2016: $50 million in a completed capital investment
    • May 2014: $30 million in a completed capital investment
    • November 2013: $20 million in a completed capital investment

    Pipeline

    Product Candidate Indication Dosage Form Status Next Anticipated Step
    AM0012 Cancer Unknown Preclinical TBA
    AM0015 Cancer Unknown Preclinical TBA
    AM0001 Cancer Parenteral Preclinical TBA
    AM0010 Solid Tumors (Renal Cell Cancer & NSCLC) Parenteral Phase I To initiate a Phase II/III trial
    AM0010e Pancreatic Cancer Parenteral Phase III TBA

    Contact Information

    ARMO BioSciences, Inc. Key Officers
    575 Chesapeake Drive Peter Van Vlasselaer, PhD, President & CEO
    Redwood City, CA, 94063 USA Martin Oft, MD, VP, Preclinical & Clinical Development
    Phone: +1-779-5075 Gail L. Brown, MD, CMO
    Web: http://www.armobio.com/index.php Melinda Whiteside, Senior Director & Head, Clinical Operations

     

    Related posts:
    Follow the Money to Pharmaceutical Opportunities – Spotlight on CymaBay Therapeutics
    Follow the Money to Pharmaceutical Opportunities – Spotlight on AveXis, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on AmpliPhi Biosciences Corporation

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu